Abstract
BackgroundThis study aimed to investigate the prognostic value of baseline hemoglobin‐to‐red blood cell distribution width ratio (HRR) in patients with small cell lung cancer (SCLC).MethodsWe retrospectively analyzed the medical records of patients with newly diagnosed SCLC who had received first‐line chemotherapy at the Department of Pulmonary Oncology of the PLA 307 Hospital between January 2008 and October 2018. The optimal cutoff value of the continuous variables was determined using the X‐tile software. Univariate and multivariate analyses were conducted using Cox proportional hazard models. The Kaplan‐Meier method was used for survival analysis, with differences tested using the log‐rank test.ResultsA total of 146 patients were included. The cutoff value for HRR was determined as 0.985. Statistically significant differences were observed in sex, smoking history, stage, radiotherapy combination, neutrophil‐to‐lymphocyte ratio, platelet‐to‐lymphocyte ratio, hemoglobin, and red blood cell distribution width between the high and low HRR groups. The median overall survival (OS) was nine and 17.5 months in the low and high HRR groups, respectively (P < 0.001). The median progression‐free survival (PFS) was five and 8.5 months, respectively (P < 0.001). Univariate and multivariate analyses showed low HRR to be an independent predictor of a poor prognosis for OS (hazard ratio = 3.782; 95% confidence interval, 2.151–6.652; P < 0.001) and PFS (hazard ratio = 2.112; 95% confidence interval, 1.195–3.733; P = 0.01) in SCLC.ConclusionLow HRR was associated with poorer OS and PFS in patients with SCLC and can be a potentially valuable prognostic factor for these patients.Key pointsThe prognostic value of the baseline hemoglobin‐to‐red blood cell distribution width ratio was evaluated in patients with small cell lung cancer.In this population, this ratio was an independent predictor of overall survival and progression‐free survival. This ratio, an inexpensive and routine parameter, can be used as a prognostic factor in small cell lung cancer.
Highlights
Small cell lung cancer (SCLC) is a highly invasive neuroendocrine tumor accounting for about 15%–20% of lung cancer cases.[1]
The inclusion criteria for the study were as follows: (i) small cell lung cancer (SCLC) diagnosed by histopathological analysis; (ii) adequate imaging data, such as CT and MRI data, for tumor staging; (iii) no previous antitumor treatment, including radiotherapy, chemotherapy, immunotherapy, and targeted treatment; (iv) an Eastern Cooperative Oncology Group (ECOG) score of 0–1; (v) complete blood test results of the hospital-based laboratory to establish hemoglobin-to-red blood cell distribution width ratio (HRR), determined within one week before chemotherapy; (vi) routine blood and blood biochemistry findings that met the requirements for chemotherapy; and (vii) signed informed consent for chemotherapy and follow-up
The most commonly used first-line chemotherapy regimen was etoposide plus lobaplatin (49.3%), followed by etoposide combined with cisplatin (41.1%) and etoposide combined with carboplatin (9.6%)
Summary
Small cell lung cancer (SCLC) is a highly invasive neuroendocrine tumor accounting for about 15%–20% of lung cancer cases.[1]. This study aimed to investigate the prognostic value of baseline hemoglobin-to-red blood cell distribution width ratio (HRR) in patients with small cell lung cancer (SCLC). Univariate and multivariate analyses showed low HRR to be an independent predictor of a poor prognosis for OS (hazard ratio = 3.782; 95% confidence interval, 2.151–6.652; P < 0.001) and PFS (hazard ratio = 2.112; 95% confidence interval, 1.195–3.733; P = 0.01) in SCLC. Key points: The prognostic value of the baseline hemoglobin-to-red blood cell distribution width ratio was evaluated in patients with small cell lung cancer. In this population, this ratio was an independent predictor of overall survival and progression-free survival. This ratio, an inexpensive and routine parameter, can be used as a prognostic factor in small cell lung cancer
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
